Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
KEYWORDS: dabigatran, warfarin, people, manufacturer, erg, treatment, daily, committee, twice daily, twice, stroke, inr, compared, years, dabigatran twice

treated with warfarin. In the appraisal consultation document, the manufacturer of dabigatran was therefore asked to provide further analyses addressing the uncertainties outlined in sections 4.11 to 4.15. 4.16 The Committee discussed the manufacturer's revised analyses and the critique and the exploratory analyses performed by the ERG. The Committee noted that the manufacturer's revised analysis included the relative risks from the whole RE- LY trial population rather than from the post hoc subgroup analysis and had explored the effect of varying the cost of INR monitoring as requested. It also noted that the manufacturer's revised analysis incorporated an INR monitoring cost of £241.54 in its base case as opposed to £414.90 in the original submission. The Committee was aware that comments received during the consultation largely agreed that INR monitoring costs are likely to be higher than the ERG's lower estimate of £115.14 and possibly higher than £414.90 in some cases. The Committee accepted the manufacturer's approach, acknowledging that although INR costs may vary widely, this assumption was reasonable. 4.17 The Committee discussed the manufacturer's approach to including the ERG's other preferred assumptions in the revised analysis (see section 3.33). The Committee noted that the Gallagher et al. (2008) data
